Physician profile
Tejaskumar A Naik
NPI 1255426599
$1,691.87
in general payments reported to CMS, 2019-2025
18 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.66 · 2020: $111 · 2021: $156 · 2022: $290 · 2023: $402 · 2024: $497 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.77 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $474.86 | 2020-2025 | Collagenase Santyl, Grafix |
| Viiv Healthcare Company | $271.36 | 2023-2025 | Dovato |
| Gilead Sciences, INC. | $116.92 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $109.50 | 2021 | |
| Kerecis Limited | $108.44 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Astellas Pharma US INC | $89.99 | 2023 | |
| Vapotherm INC | $87.34 | 2022 | |
| Abbvie INC. | $74.67 | 2023-2024 | |
| Theratechnologies INC. | $55.36 | 2025 | Egrifta, Trogarzo |
| Aimmune Therapeutics, INC. | $52.72 | 2023 | |
| Bard Peripheral Vascular, INC. | $49.83 | 2022 | |
| Paratek Pharmaceuticals, INC. | $45.25 | 2024-2025 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $38.54 | 2020 | |
| Merck Sharp & Dohme LLC | $34.34 | 2019 | |
| Insmed, INC. | $29.76 | 2023-2024 | Arikayce |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $22.56 | 2024 | Rebyota |
| Kci USA, INC. | $16.11 | 2020 | |
| Allergan, INC. | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejaskumar Naik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.